Abstract: Selinexor (KPT-330) is a first-in-class, orally bioavailable Selective Inhibitor of Nuclear Export (SINE) that specifically targets the nuclear export protein exportin-1 (XPO1/CRM1). By blocking XPO1, selinexor forces the nuclear retention and reactivation of key tumor suppressor proteins (such as p53, p21, and p27) and reduces the cytoplasmic translation of oncogenic mRNAs. While selinexor has been extensively studied and approved for hematological malignancies, emerging clinical evidence highlights its significant potential in solid tumors, particularly endometrial cancer. Recent clinical trials have demonstrated that selinexor exhibits promising pharmacological activity in advanced and recurrent endometrial cancer, both as a monotherapy and in combination with standard chemotherapies. Notably, phase III data indicate a substantial progression-free survival benefit when selinexor is used as maintenance therapy in patients with p53 wild-type endometrial cancer. This review synthesizes the current literature on selinexor with a specific focus on its application in endometrial cancer, detailing its molecular mechanism of action, structure-activity relationship, current clinical limitations, and future therapeutic perspectives.
1. Introduction
Exportin-1 (XPO1), also known as chromosomal region maintenance 1 (CRM1), is a key regulatory protein responsible for the nuclear-to-cytoplasmic transport of over 200 cargo proteins, including major tumor suppressor proteins (TSPs) and growth regulatory factors [1][4]. In a wide variety of malignancies, XPO1 is overexpressed, which correlates with advanced disease, resistance to therapy, and poor overall survival [4][7]. The overexpression of XPO1 leads to the aberrant cytoplasmic accumulation and subsequent functional inactivation of TSPs, allowing cancer cells to evade apoptosis and proliferate unchecked [9].
Selinexor (KPT-330) is an oral, potent, and slowly reversible Selective Inhibitor of Nuclear Export (SINE) compound designed to specifically block XPO1 [4]. While selinexor has achieved regulatory approval for the treatment of relapsed/refractory multiple myeloma and diffuse large B-cell lymphoma [1][3], its application in solid tumors is an area of active investigation. In the realm of gynecologic oncology, endometrial cancer (EC) has emerged as a highly promising research direction for selinexor, driven by clinical trial data showing notable efficacy, particularly in specific molecular subtypes of the disease [1].
2. Pharmacological Activity
The pharmacological activity of selinexor in endometrial cancer has been evaluated across multiple phases of clinical trials, demonstrating its viability both as a combination agent and as a maintenance therapy.
In a Phase I open-label study (NCT02269293), the safety and efficacy of selinexor were evaluated in combination with paclitaxel and carboplatin in 23 patients with advanced ovarian or endometrial cancers. The results were encouraging, with a notable treatment effect observed in 56.5% (13/23) of the patients. Specifically, 4.3% (1/23) achieved a complete response (CR), 52.2% (12/23) achieved a partial response (PR), and 13% had stable disease (SD) [1].
Further evidence of efficacy was observed in a Phase II study (NCT02025985) examining selinexor in recurrent gynecologic tumors. Following Phase I treatment, which included 23 patients with endometrial cancer, the disease control rate (DCR) for the EC cohort was 35% [1]. Additionally, a multi-arm Phase Ib clinical trial (NCT02419495) investigated selinexor in combination with topotecan in patients with various gynecological malignancies, including two patients with endometrial cancer, demonstrating moderate tolerance and stable disease in a subset of the cohort [1].
The most compelling pharmacological data for selinexor in endometrial cancer comes from a randomized, prospective, multicenter, double-blind, placebo-controlled Phase III study (NCT03555422). This trial enrolled 263 patients with advanced or recurrent EC who were randomly assigned to receive oral selinexor (80 mg once weekly) or placebo as maintenance therapy following first-line combination chemotherapy. Crucially, the study identified a profound benefit in a specific molecular subgroup: patients with p53 wild-type (WT) endometrial cancer exhibited a median progression-free survival (PFS) of 13.7 months when treated with selinexor, compared to only 3.7 months for those receiving the placebo. These findings strongly suggest that selinexor plays an important role in maintenance therapy for p53 WT endometrial cancers [1].
3. Molecular Mechanism of Action
The primary molecular mechanism of action of selinexor involves the targeted inhibition of XPO1-mediated nuclear export. By blocking XPO1, selinexor forces the nuclear retention and reactivation of critical tumor suppressor proteins, including p53, p21, p27, FOXO3A, and IκB [1][8][9]. The nuclear accumulation of these proteins restores their tumor-suppressive functions, leading to cell cycle arrest and the induction of apoptosis in malignant cells [7].
In addition to retaining TSPs in the nucleus, XPO1 inhibition disrupts the cytoplasmic localization and translation of key proto-oncogenic mRNAs. XPO1 regulates the export of mRNAs (such as c-MYC) that complex with the eukaryotic translation initiation factor 4E (eIF4E) cargo protein. Selinexor treatment suppresses the translation and expression of these oncoproteins, including c-MYC, Bcl-xL, and Mcl-1, further crippling the survival mechanisms of the cancer cells [1][2][4].
In the specific context of endometrial cancer, the mechanism of selinexor is intimately tied to the p53 pathway. The pronounced clinical benefit observed in p53 wild-type endometrial cancer patients underscores that selinexor's efficacy is highly dependent on the nuclear accumulation and functional reactivation of the wild-type p53 tumor suppressor protein, which subsequently drives the apoptotic response in these tumor cells [1].
4. Structure-Activity Relationship (SAR)
Selinexor belongs to a class of small molecules known as SINE compounds, which are designed with N-azolylacrylate derivatives [9]. The structure-activity relationship of SINE compounds is defined by their ability to specifically bind to the Cys528 residue located in the cargo-binding groove of the XPO1/CRM1 protein [3].
Historically, the first-generation XPO1 inhibitor, leptomycin B, bound to XPO1 irreversibly. While mechanistically effective, this irreversible binding crippled nuclear export in normal cells as well, leading to severe, dose-limiting systemic toxicities (such as profound anorexia and malaise) that halted its clinical development [8][11]. In contrast, selinexor and other SINE compounds (e.g., KPT-185, KPT-276, KPT-8602) form a slowly reversible covalent bond with Cys528 [3][4]. This transient target inhibition provides a much-improved therapeutic window, allowing for potent anti-tumor activity while maintaining a relatively lower toxicity profile compared to earlier inhibitors [3][8].
5. Current Limitations
Despite its clinical efficacy, the use of selinexor is constrained by several limitations, primarily related to its toxicity profile and the emergence of drug resistance.
Toxicity: Because XPO1 is widely expressed and required for normal cellular functions, systemic toxicities are common. The most frequently reported adverse events are gastrointestinal and constitutional, including nausea, vomiting (emesis), decreased appetite, weight loss, and fatigue [2][3]. Hematological toxicities are also highly prevalent and often represent grade 3 or 4 adverse events; these include thrombocytopenia, neutropenia, leukopenia, and anemia [1][4]. Electrolyte abnormalities, particularly hyponatremia, are also frequently observed and require careful clinical management and supportive care [2][8].
Drug Resistance: Resistance to XPO1 inhibition remains a challenge. Preclinical models have demonstrated that a CRISPR-induced heterozygous mutation in the XPO1 cargo-binding pocket (C528S) renders the protein resistant to selinexor binding and degradation [2]. Beyond direct target mutations, cancer cells can develop resistance through alternative molecular pathways, such as the upregulation of NF-κB signaling, alterations in the TGF-β/SMAD pathway, and changes in ESF1 transcription activity [2]. Long-term use of SINEs may also induce resistance via pathways like NRG1/EBB3 signaling [1].
6. Future Perspectives
The future of selinexor in endometrial cancer and other solid tumors lies in optimized combination regimens, biomarker-driven patient selection, and the development of next-generation inhibitors.
Combination Therapies: Preclinical and clinical data suggest that selinexor exhibits marked synergy when combined with standard chemotherapies (e.g., paclitaxel, carboplatin, topotecan) and targeted agents [1][3]. Combination strategies can help overcome acquired resistance—for instance, combining selinexor with proteasome inhibitors has been shown to re-sensitize resistant cells by forcing the nuclear retention of IκB and deactivating NF-κB [2][9]. Further exploration of these combinations in endometrial cancer is warranted to maximize therapeutic efficacy.
Biomarker-Driven Approaches: The striking PFS benefit observed in the Phase III trial for p53 wild-type endometrial cancer patients highlights the critical need for biomarker-driven treatment strategies [1]. Future clinical applications in endometrial cancer will likely prioritize molecular profiling to identify p53 WT patients who are most likely to benefit from selinexor as a maintenance therapy.
Next-Generation SINE Compounds: To address the toxicity limitations of selinexor, second-generation XPO1 inhibitors, such as eltanexor (KPT-8602), have been rationally designed. These newer agents feature increased reversibility and limited blood-brain barrier penetration, which significantly reduces central nervous system-related toxicities (such as anorexia and weight loss) while maintaining potent anti-tumor activity [2][8]. The integration of these next-generation compounds into clinical trials may offer a wider therapeutic index for patients with endometrial cancer.
